PROK

ProKidney

• TipRanks·03/25 20:05

  ProKidney appoints Greg Madison as chief commercial officer

• Reuters·03/25 20:01

  ProKidney appoints Greg Madison chief commercial officer; senior leadership team expands

• Dow Jones·03/25 20:01

  Press Release: ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

• TipRanks·03/25 15:10

  Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), LENZ Therapeutics (LENZ) and Sarepta Therapeutics (SRPT)

• TipRanks·03/20 06:01

  Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability

• TipRanks·03/19 13:20

  Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)

• TipRanks·03/19 11:17

  Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)

• TipRanks·03/19 11:15

  ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating

• TipRanks·03/19 10:56

  Guggenheim Sticks to Its Buy Rating for ProKidney (PROK)

• TipRanks·03/19 10:33

  Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Dogwood Therapeutics (DWTX) and Precision BioSciences (DTIL)

• NASDAQ·03/19 05:52

  ProKidney Expects Phase 3 PROACT 1 Pivotal Trial Results For Rilparencel In Q2 2027

• Dow Jones·03/18 20:16

  *ProKidney On Track to Complete Enrollment for Phase 3 PROACT 1 Accelerated Approval Analysis of Rilparencel in Mid-2026 >PROK

• Dow Jones·03/18 20:16

  *ProKidney Ended 2025 With $270 M in Cash and Cash Equivalents and Marketable Securities, Supporting Ops Into Mid-2027 >PROK

• TipRanks·03/18 20:05

  ProKidney reports Q4 EPS (52c), consensus (15c)

• Dow Jones·03/18 20:01

  *ProKidney FY25 Rev $893,000 >PROK